URGN Quote, Financials, Valuation and Earnings

ACADIA Pharmaceuticals has a net margin of -216.47% compared to UroGen Pharma's net margin of 7.77%. UroGen Pharma's return on equity of -- beat ACADIA Pharmaceuticals's return on equity of 37.45%.

UroGen Pharma has a consensus price target of $34.38, signalling upside risk potential of 123.07%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $28.74 which suggests that it could grow by 27.44%. Given that UroGen Pharma has higher upside potential than ACADIA Pharmaceuticals, analysts believe UroGen Pharma is more attractive than ACADIA Pharmaceuticals.

UroGen Pharma has a beta of 1.017, which suggesting that the stock is 1.724% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.641, suggesting its less volatile than the S&P 500 by 35.902%.

UroGen Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.

UroGen Pharma quarterly revenues are $20.3M, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $244.3M. UroGen Pharma's net income of -$43.8M is lower than ACADIA Pharmaceuticals's net income of $19M. Notably, UroGen Pharma's price-to-earnings ratio is -- while ACADIA Pharmaceuticals's PE ratio is 16.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma is 7.78x versus 3.77x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical has a net margin of -216.47% compared to UroGen Pharma's net margin of 24.92%. UroGen Pharma's return on equity of -- beat BioMarin Pharmaceutical's return on equity of 9.62%.

UroGen Pharma has a consensus price target of $34.38, signalling upside risk potential of 123.07%. On the other hand BioMarin Pharmaceutical has an analysts' consensus of $95.69 which suggests that it could grow by 63.95%. Given that UroGen Pharma has higher upside potential than BioMarin Pharmaceutical, analysts believe UroGen Pharma is more attractive than BioMarin Pharmaceutical.

UroGen Pharma has a beta of 1.017, which suggesting that the stock is 1.724% more volatile than S&P 500. In comparison BioMarin Pharmaceutical has a beta of 0.168, suggesting its less volatile than the S&P 500 by 83.229%.

UroGen Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma pays -- of its earnings as a dividend. BioMarin Pharmaceutical pays out -- of its earnings as a dividend.

UroGen Pharma quarterly revenues are $20.3M, which are smaller than BioMarin Pharmaceutical quarterly revenues of $745.1M. UroGen Pharma's net income of -$43.8M is lower than BioMarin Pharmaceutical's net income of $185.7M. Notably, UroGen Pharma's price-to-earnings ratio is -- while BioMarin Pharmaceutical's PE ratio is 21.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma is 7.78x versus 3.91x for BioMarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Fortrea Holdings has a net margin of -216.47% compared to UroGen Pharma's net margin of -86.43%. UroGen Pharma's return on equity of -- beat Fortrea Holdings's return on equity of -58.22%.

UroGen Pharma has a consensus price target of $34.38, signalling upside risk potential of 123.07%. On the other hand Fortrea Holdings has an analysts' consensus of $6.66 which suggests that it could grow by 34.53%. Given that UroGen Pharma has higher upside potential than Fortrea Holdings, analysts believe UroGen Pharma is more attractive than Fortrea Holdings.

UroGen Pharma has a beta of 1.017, which suggesting that the stock is 1.724% more volatile than S&P 500. In comparison Fortrea Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UroGen Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortrea Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma pays -- of its earnings as a dividend. Fortrea Holdings pays out -- of its earnings as a dividend.

UroGen Pharma quarterly revenues are $20.3M, which are smaller than Fortrea Holdings quarterly revenues of $651.3M. UroGen Pharma's net income of -$43.8M is higher than Fortrea Holdings's net income of -$562.9M. Notably, UroGen Pharma's price-to-earnings ratio is -- while Fortrea Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma is 7.78x versus 0.17x for Fortrea Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Organon & has a net margin of -216.47% compared to UroGen Pharma's net margin of 5.75%. UroGen Pharma's return on equity of -- beat Organon &'s return on equity of 220.72%.

UroGen Pharma has a consensus price target of $34.38, signalling upside risk potential of 123.07%. On the other hand Organon & has an analysts' consensus of $13.33 which suggests that it could grow by 38.31%. Given that UroGen Pharma has higher upside potential than Organon &, analysts believe UroGen Pharma is more attractive than Organon &.

UroGen Pharma has a beta of 1.017, which suggesting that the stock is 1.724% more volatile than S&P 500. In comparison Organon & has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

UroGen Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & offers a yield of 8.92% to investors and pays a quarterly dividend of $0.02 per share. UroGen Pharma pays -- of its earnings as a dividend. Organon & pays out 34.38% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UroGen Pharma quarterly revenues are $20.3M, which are smaller than Organon & quarterly revenues of $1.5B. UroGen Pharma's net income of -$43.8M is lower than Organon &'s net income of $87M. Notably, UroGen Pharma's price-to-earnings ratio is -- while Organon &'s PE ratio is 3.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma is 7.78x versus 0.40x for Organon &. Usually stocks with elevated PS ratios are considered overvalued.